ResearcherRutgers New Jersey Medical SchoolActive in the last 2 years
Pingping Hou
Matched on ORCID iD 0000-0002-2429-0861; OpenAlex author ID A5028876812. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 30
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 6
- NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer. Last author DOI 10.1084/jem.20240766↗
- Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00500-z↗
- Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance. Last author DOI 10.3390/cells11192952↗
- USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. Co-author DOI 10.1101/gad.348787.121↗
- Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0597↗
- Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daiyong Deng · 2 shared papers, 2022–2024 · strength 0.43
- Ronald Anthony Depinho · 4 shared papers, 2019–2023 · strength 0.39
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z↗
- Paper USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. DOI 10.1101/gad.348787.121↗
- Paper Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-0597↗
- Habeebunnisa Begum · 1 shared paper, 2024 · strength 0.20
- Jianhua Zhang · 2 shared papers, 2020–2021 · strength 0.20
- Huamin Wang · 2 shared papers, 2019–2023 · strength 0.19
- Haoqiang Ying · 2 shared papers, 2019–2023 · strength 0.19
- Anirban Maitra · 2 shared papers, 2019–2023 · strength 0.19
- Yan Liang · 2 shared papers, 2019–2021 · strength 0.17
- Wantong Yao · 2 shared papers, 2019–2021 · strength 0.17
- Avnish Kapoor · 2 shared papers, 2019–2020 · strength 0.15
- Aislyn P. Schalck · 1 shared paper, 2023 · strength 0.13
- Jincheng Han · 1 shared paper, 2023 · strength 0.13
- Pat Gulhati · 1 shared paper, 2023 · strength 0.13
- Michael P. Kim · 1 shared paper, 2023 · strength 0.13
- Prasenjit Dey · 1 shared paper, 2023 · strength 0.13
- Qiang Zhang · 1 shared paper, 2021 · strength 0.11
- Alec C. Kimmelman · 1 shared paper, 2021 · strength 0.11
- Qiang Zhang · 1 shared paper, 2020 · strength 0.09
- Raghu Kalluri · 1 shared paper, 2020 · strength 0.09
- Andrea Viale · 1 shared paper, 2019 · strength 0.06
- Alessandro Carugo · 1 shared paper, 2019 · strength 0.06
- Piergiorgio Pettazzoni · 1 shared paper, 2019 · strength 0.06
- Timothy Paul Heffernan · 1 shared paper, 2019 · strength 0.06
- I-Lin Ho · 1 shared paper, 2019 · strength 0.06
- Jun Yao · 1 shared paper, 2019 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.